Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026
← Back to Research Index
Compare Evaluate Matrix Half-Life
Dossier · № 106 of 110 Updated Nov 17, 2026

Wolverine

Wolverine stack · BPC-157 + TB-500 · healing blend · tissue-repair stack

ANECDOTAL · COMBINATION PEPTIDE STACK

▓ 1 indexed citations across EuropePMC (1).

Citation breakdown by evidence tier

← weaker evidence  ·  stronger evidence →

1 citation across 1 tier

Tap any tier to jump to that section of the bibliography.

Mechanism of action

Combined cytoprotective + actin regulation (see individual entries)

Researched effects

Synergistic tissue repair; faster recovery (anecdotal)

Live evidence

Live signals refreshed daily. Current as of November 19, 2026.

Dosing reported in literature

BPC 250-500 mcg + TB 2 mg SC daily or split weekly

Known concerns

Combined risk profile of both; no combination safety trials

Full citation library

Year distribution

Preprints (not yet peer-reviewed)

1
  1. 1.

    Venkatakrishnan A, Marwaha A, Gregg CJ, Varma G, Hurchik M, Murugadoss K, Shivabasappa S, Soundararajan V. · 2026

    Body Protection Compound-157 (BPC-157) is an unapproved synthetic peptide marketed directly to consumers despite limited human evidence on benefits and risks. We characterized the use of BPC-157 and patient-reported outcomes from 2020 through 2026 using Large Language Model (LLM) curation of de-identified clinical notes from a U.S. federated network with physician validation of each LLM-curation exercise. Of 1,536 patients with a note mentioning BPC-157, 1,039 (67.6%) had documented use, and qua…

Curated sources on file

3
  1. 1.
  2. 2.
  3. 3.
    Note: This is a combination/stack entry. No independent indexed primary literature exists for the BPC-157 + TB-500 combination; cited papers describe each component separately.

Continue reading